Pareto and Analysguiden publish research reports
Hørsholm, Denmark, 16 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in March. Both sponsored research analysts commented on the recently announced rights issue and MucoVax collaboration. Analysguiden reduced its price target to SEK 12 per share, primarily a result of dilution from the rights issue and updates to its estimates for ABNCoV2, the COVID-19 vaccine candidate.
The Analysguiden report dives deeper into recent topics related to the COVID-19 vaccine, including upcoming milestones, the 26 January 2023 FDA advisory committee meeting, Bavarian Nordic’s expected payments to ExpreS2ion associated company and partner in the COVID-19 vaccine, AdaptVac, and vaccination trends. Furthermore, Analyst Sten Westerberg comments on the rights issue, recently formed infectious diseases advisory board, and recently announced mucosal vaccine program.
The research reports are available on the Analyst Reports page of ExpreS2ion’s investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.